HUTCHMED

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 20, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

<!-- Name:DistributionId Value:8805759 --> <!--…
Read More...

<!-- Name:DistributionId Value:8799000 --> <!--…
Read More...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

— Company plans to complete rolling submission to the U.S. in the first half of 2023, followed by filings in Europe and…
Read More...

— Results of dual primary endpoint study showed statistically significant and clinically meaningful benefit in…
Read More...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited…
Read More...

SAN DIEGO and SHANGHAI, China and HONG KONG, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Inmagene Biopharmaceuticals…
Read More...

— MET is the most common biomarker in patients with EGFR-mutated lung cancer who develop resistance to targeted therapy…
Read More...